CD19 and acute lymphoblastic leukemia: Pivotal clinical trials of CD19-directed CAR-T (CART19) cell therapy demonstrated unprecedented results in non-CNS B-cell lymphomas and acute lymphoblastic leukemia (ALL), leading to several FDA approvals of CART19 cell products (10–21).